Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CARLOS A SESIN

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1659304707
CMS profile
74196
Location
MIAMI BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$276,438.27

561 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 8 of 12; records 351–400 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CARLOS A SESIN

NPI 1659304707 · CMS profile ID 74196

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

MIAMI BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 8 of 12; records 351–400 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659304707?year=2019&recipient=provider&page=8#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CARLOS A SESIN, NPI 1659304707, CMS profile ID 74196. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 12; records 351–400 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659304707?year=2019&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CARLOS A SESIN, NPI 1659304707, CMS profile ID 74196. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 12; records 351–400 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659304707?year=2019&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CARLOS A SESIN, NPI 1659304707, CMS profile ID 74196, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 8 of 12; records 351–400 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1659304707?year=2019&recipient=provider&page=8#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

561 matching records · $276,438.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 561 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 351–400 of 561.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $34.0004/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662233865 CMS
Amgen Inc. $110.2404/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662233891 CMS
Amgen Inc. $2,000.0004/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662233895 CMS
Radius Health, Inc. $12.1604/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931791 CMS
GENZYME CORPORATION $13.2304/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694000235 CMS
Amgen Inc. $25.2604/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662233839 CMS
PFIZER INC. $20.6204/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672675629 CMS
Genentech USA, Inc. $18.4803/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681267965 CMS
Radius Health, Inc. $16.0503/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931665 CMS
Radius Health, Inc. $136.3103/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931669 CMS
Radius Health, Inc. $121.7503/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931671 CMS
Radius Health, Inc. $3,150.0003/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931675 CMS
Radius Health, Inc. $39.8603/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931781 CMS
Radius Health, Inc. $215.8003/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931783 CMS
Radius Health, Inc. $601.0003/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931785 CMS
Radius Health, Inc. $136.3003/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931787 CMS
Radius Health, Inc. $3,150.0003/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931807 CMS
Radius Health, Inc. $215.8003/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931809 CMS
Radius Health, Inc. $601.0003/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931811 CMS
Janssen Biotech, Inc. $1.7503/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658705113 CMS
AbbVie, Inc. $1,500.0003/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648027547 CMS
Amgen Inc. $2,400.0003/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662233875 CMS
Amgen Inc. $2,400.0003/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662233845 CMS
Amgen Inc. $400.0003/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662233847 CMS
Novartis Pharmaceuticals Corporation $2,525.0003/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660001629 CMS
Novartis Pharmaceuticals Corporation $125.0003/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660001631 CMS
Janssen Biotech, Inc. $14.2403/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658705109 CMS
Radius Health, Inc. $16.5403/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931571 CMS
Radius Health, Inc. $1,800.0003/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931663 CMS
Radius Health, Inc. $119.9203/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931677 CMS
Regeneron Healthcare Solutions, Inc. $398.5903/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673473111 CMS
Regeneron Healthcare Solutions, Inc. $35.2503/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673473113 CMS
AbbVie, Inc. $61.1203/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648027545 CMS
Horizon Therapeutics plc $12.5903/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691492177 CMS
Janssen Biotech, Inc. $11.3103/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658705106 CMS
Lilly USA, LLC $9.5503/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657703813 CMS
Amgen Inc. $2,400.0003/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662233827 CMS
Amgen Inc. $2,400.0003/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662233829 CMS
Amgen Inc. $400.0003/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662233831 CMS
Amgen Inc. $2,400.0003/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662233851 CMS
Amgen Inc. $800.0003/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662233859 CMS
Amgen Inc. $2,400.0003/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662233877 CMS
Amgen Inc. $400.0003/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662233879 CMS
Radius Health, Inc. $1,800.0003/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931655 CMS
Radius Health, Inc. $19.2503/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931661 CMS
Amgen Inc. $486.4003/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662233841 CMS
Hikma Pharmaceuticals USA $19.9703/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688411887 CMS
AbbVie, Inc. $19.6203/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648027445 CMS
Amgen Inc. $124.9903/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662233843 CMS
Janssen Biotech, Inc. $3.7403/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658705103 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $276,438.27 561
PY2020 $87,515.40 317
PY2021 $76,643.29 301
PY2022 $53,342.42 286
PY2023 $55,421.63 262
PY2024 $43,683.55 225
PY2025 $57,825.78 212

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,028.67 1
PY2025 Principal investigator $4,385,061.95 203
PY2024 Recipient $2,373.83 1
PY2024 Principal investigator $3,202,518.40 147
PY2023 Recipient $2,057.42 11
PY2023 Principal investigator $6,400,939.84 6,837
PY2022 Principal investigator $3,639,774.67 4,755
PY2021 Principal investigator $415,351.54 124
PY2020 Principal investigator $343,754.28 77
PY2019 Principal investigator $3,545.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

204 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $1,685.78 12/19/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977379
Principal investigator 1 ModernaTX, Inc. $14,484.08 12/19/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977423
Principal investigator 1 ModernaTX, Inc. $89,564.67 12/19/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977475
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,610.44 12/17/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289774
Principal investigator 1 ABBVIE INC. $12,982.40 12/04/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202526870
Principal investigator 1 ABBVIE INC. $3,294.84 12/04/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202526872
Principal investigator 1 ModernaTX, Inc. $16,773.90 12/04/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977473
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,917.76 12/01/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288865
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 12/01/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288945
Principal investigator 1 ModernaTX, Inc. $9,271.79 11/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977413
Principal investigator 1 ModernaTX, Inc. $69,157.53 11/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977421
Principal investigator 1 ModernaTX, Inc. $16,341.52 11/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977463
Principal investigator 1 ModernaTX, Inc. $33,952.62 11/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977485
Principal investigator 1 ModernaTX, Inc. $7,000.00 11/21/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977357
Principal investigator 1 ModernaTX, Inc. $1,900.00 11/21/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977361
Principal investigator 1 ModernaTX, Inc. $1,365.00 11/21/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977443
Principal investigator 1 ModernaTX, Inc. $3,524.10 11/21/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977461
Principal investigator 1 ModernaTX, Inc. $2,160.90 11/21/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977467
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,052.00 11/19/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
INSPIRE LTE study No dispute reported 06/30/2026 1246434791
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $21,195.44 11/19/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288491
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $15,458.08 11/12/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246434833
Principal investigator 1 ABBVIE INC. $19,207.15 11/05/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202521685
Principal investigator 1 ABBVIE INC. $5,802.36 11/04/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520299
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,211.00 11/03/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223287897
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,085.00 11/03/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223287899
Principal investigator 1 ModernaTX, Inc. $1,685.78 10/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977365
Principal investigator 1 ModernaTX, Inc. $12,488.32 10/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977471
Principal investigator 1 ModernaTX, Inc. $15,195.44 10/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977477
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 10/24/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223287647
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,790.72 10/15/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286949
Principal investigator 1 ABBVIE INC. $10,431.51 10/09/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202514649
Principal investigator 1 ABBVIE INC. $9,167.00 10/09/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202514785
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,459.96 10/03/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286301
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,000.40 10/02/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
INSPIRE LTE study No dispute reported 06/30/2026 1246434804
Principal investigator 1 ModernaTX, Inc. $15,531.36 09/29/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977419
Principal investigator 1 ModernaTX, Inc. $32,781.84 09/29/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977495
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24,428.88 09/19/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285722
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,343.20 09/19/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285724
Principal investigator 1 ABBVIE INC. $125.00 09/04/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202509576
Principal investigator 1 ABBVIE INC. $6,166.86 09/03/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202508084
Principal investigator 1 ABBVIE INC. $7,500.00 09/02/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202506965
Principal investigator 1 ABBVIE INC. $4,500.00 09/02/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202506967
Principal investigator 1 ABBVIE INC. $1,050.00 09/02/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202506969
Principal investigator 1 ABBVIE INC. $1,200.00 09/02/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202506971
Principal investigator 1 ModernaTX, Inc. $1,900.00 09/01/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977459
Principal investigator 1 ModernaTX, Inc. $650.00 09/01/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977479
Principal investigator 1 ABBVIE INC. $750.00 08/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202506351
Principal investigator 1 ABBVIE INC. $700.00 08/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202506353
Principal investigator 1 ModernaTX, Inc. $842.89 08/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977353
Principal investigator 1 ModernaTX, Inc. $23,805.86 08/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977369
Principal investigator 1 ModernaTX, Inc. $107,664.83 08/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977411
Principal investigator 1 ModernaTX, Inc. $16,242.72 08/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977465
Principal investigator 1 ModernaTX, Inc. $1,437.91 08/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007127
Principal investigator 1 ModernaTX, Inc. $276.64 08/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007187
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,401.16 08/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223284619
Principal investigator 1 ModernaTX, Inc. $2,112.00 08/14/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977345
Principal investigator 1 ABBVIE INC. $4,100.00 08/05/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202501370
Principal investigator 1 ABBVIE INC. $4,778.18 08/05/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202501372
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,343.20 08/01/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283439
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,619.56 08/01/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283441
Principal investigator 1 ABBVIE INC. $2,200.00 07/31/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202500660
Principal investigator 1 ModernaTX, Inc. $1,951.30 07/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977417
Principal investigator 1 ModernaTX, Inc. $31,944.51 07/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977427
Principal investigator 1 ModernaTX, Inc. $842.89 07/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977509
Principal investigator 1 ModernaTX, Inc. $4,110.08 07/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977515
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,867.20 07/23/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
INSPIRE LTE study No dispute reported 06/30/2026 1246434777
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $290.70 07/16/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
INSPIRE LTE study No dispute reported 06/30/2026 1246434874
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $16,637.61 07/07/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246434810
Principal investigator 1 ABBVIE INC. $34,498.05 07/02/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202495329
Principal investigator 1 ModernaTX, Inc. $34,733.14 06/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977371
Principal investigator 1 ModernaTX, Inc. $842.89 06/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977391
Principal investigator 1 ModernaTX, Inc. $7,098.78 06/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977455
Principal investigator 1 ModernaTX, Inc. $11,559.60 06/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977511
Principal investigator 1 ModernaTX, Inc. $19.76 06/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007159
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $19,924.00 06/25/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246434782
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,530.40 06/25/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
INSPIRE LTE study No dispute reported 06/30/2026 1246434787
Principal investigator 1 ABBVIE INC. $890.54 06/20/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202492573
Principal investigator 1 ModernaTX, Inc. $49,563.02 06/18/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977349
Principal investigator 1 ModernaTX, Inc. $15,630.16 06/18/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977481
Principal investigator 1 ModernaTX, Inc. $197.60 06/18/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977483
Principal investigator 1 ModernaTX, Inc. $108,847.96 06/18/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977503
Principal investigator 1 ModernaTX, Inc. $19.76 06/18/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007125
Principal investigator 1 ModernaTX, Inc. $107,646.57 06/18/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007161
Principal investigator 1 ABBVIE INC. $22,750.00 06/17/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202491765
Principal investigator 1 ABBVIE INC. $100.00 06/03/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202488299
Principal investigator 1 ModernaTX, Inc. $15,906.80 05/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977363
Principal investigator 1 ModernaTX, Inc. $59,156.50 05/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977375
Principal investigator 1 ModernaTX, Inc. $80,003.30 05/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977381
Principal investigator 1 ModernaTX, Inc. $842.89 05/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977441
Principal investigator 1 ModernaTX, Inc. $10,065.37 05/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007129
Principal investigator 1 ModernaTX, Inc. $79,295.21 05/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007131
Principal investigator 1 ModernaTX, Inc. $29,185.52 05/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007177
Principal investigator 1 ModernaTX, Inc. $38,896.00 05/22/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007171
Principal investigator 1 ABBVIE INC. $300.00 05/15/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202485099
Principal investigator 1 ABBVIE INC. $1,701.00 05/15/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202485101
Principal investigator 1 ABBVIE INC. $700.00 05/15/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202485195
Principal investigator 1 ABBVIE INC. $7,500.00 05/15/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202485197
Principal investigator 1 ABBVIE INC. $1,750.00 05/15/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202485199
Principal investigator 1 ABBVIE INC. $492.00 05/14/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202484865
Principal investigator 1 ABBVIE INC. $3,800.00 05/14/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202484867
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $100.80 05/07/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
INSPIRE LTE study No dispute reported 06/30/2026 1246434813
Principal investigator 1 ABBVIE INC. $11,547.21 05/06/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202482275
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $17,108.00 05/02/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
INSPIRE LTE study No dispute reported 06/30/2026 1246434825
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,033.00 05/01/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223278766
Principal investigator 1 ModernaTX, Inc. $11,421.28 04/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977355
Principal investigator 1 ModernaTX, Inc. $842.89 04/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977401
Principal investigator 1 ModernaTX, Inc. $80,393.56 04/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977409
Principal investigator 1 ModernaTX, Inc. $1,168.31 04/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977437
Principal investigator 1 ModernaTX, Inc. $4,050.80 04/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977453
Principal investigator 1 ModernaTX, Inc. $28,098.72 04/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977501
Principal investigator 1 ModernaTX, Inc. $4,313.73 04/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007139
Principal investigator 1 ModernaTX, Inc. $29,680.33 04/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007141
Principal investigator 1 ModernaTX, Inc. $600.00 04/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007145
Principal investigator 1 ModernaTX, Inc. $1,000.00 04/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007147
Principal investigator 1 ModernaTX, Inc. $1,981.31 04/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007149
Principal investigator 1 ModernaTX, Inc. $27,407.12 04/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007157
Principal investigator 1 ModernaTX, Inc. $14,379.10 04/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007163
Principal investigator 1 ModernaTX, Inc. $6,201.86 04/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007179
Principal investigator 1 ModernaTX, Inc. $8,931.52 04/28/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007183
Principal investigator 1 ModernaTX, Inc. $500.00 04/23/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007143
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,250.40 04/23/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
INSPIRE LTE study No dispute reported 06/30/2026 1246434845
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,338.82 04/16/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246434816
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $19,530.00 04/11/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223277892
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $153.68 04/04/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
INSPIRE LTE study No dispute reported 06/30/2026 1246434870
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $14,322.00 04/02/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434829
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,520.85 04/02/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246434861
Principal investigator 1 ModernaTX, Inc. $2,500.00 03/31/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252977343
Principal investigator 1 ModernaTX, Inc. $4,500.00 03/31/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252977407
Principal investigator 1 ModernaTX, Inc. $1,365.00 03/31/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252977449
Principal investigator 1 ModernaTX, Inc. $1,000.00 03/31/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252977451
Principal investigator 1 ModernaTX, Inc. $2,400.00 03/31/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252977491
Principal investigator 1 ModernaTX, Inc. $10,000.00 03/31/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252977493
Principal investigator 1 ModernaTX, Inc. $94,633.11 03/24/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977351
Principal investigator 1 ModernaTX, Inc. $3,371.56 03/24/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977373
Principal investigator 1 ModernaTX, Inc. $15,393.04 03/24/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977457
Principal investigator 1 ModernaTX, Inc. $79.04 03/24/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977487
Principal investigator 1 ModernaTX, Inc. $69,466.28 03/24/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977519
Principal investigator 1 ModernaTX, Inc. $56,259.73 03/24/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007151
Principal investigator 1 ModernaTX, Inc. $2,984.37 03/24/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007153
Principal investigator 1 ModernaTX, Inc. $30,196.11 03/24/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007167
Principal investigator 1 ModernaTX, Inc. $33,572.24 03/24/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007175
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $46,248.27 03/21/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246434849
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,250.00 03/21/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434852
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,696.00 03/21/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246434857
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,426.08 03/14/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434837
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,976.00 03/14/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434841
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,544.00 03/12/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434820
Principal investigator 1 Eli Lilly and Company $847.60 03/11/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC DBA NEOCLINICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187890104
Principal investigator 1 ABBVIE INC. $3,118.06 03/06/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202456735
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,610.00 03/03/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
INSPIRE LTE study No dispute reported 06/30/2026 1246434795
Principal investigator 1 ModernaTX, Inc. $317,320.90 02/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977389
Principal investigator 1 ModernaTX, Inc. $50,237.33 02/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977393
Principal investigator 1 ModernaTX, Inc. $16,558.88 02/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977425
Principal investigator 1 ModernaTX, Inc. $1,685.78 02/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977469
Principal investigator 1 ModernaTX, Inc. $20,866.56 02/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977499
Principal investigator 1 ModernaTX, Inc. $107,711.76 02/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977517
Principal investigator 1 ModernaTX, Inc. $24,444.47 02/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007137
Principal investigator 1 ModernaTX, Inc. $60,246.64 02/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007155
Principal investigator 1 ModernaTX, Inc. $36,299.12 02/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007165
Principal investigator 1 ModernaTX, Inc. $7,958.32 02/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007169
Principal investigator 1 ABBVIE INC. $1,250.00 02/10/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1202450282
Principal investigator 1 ABBVIE INC. $1,383.75 02/06/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1202446708
Principal investigator 1 ABBVIE INC. $1,383.75 02/06/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1202446712
Principal investigator 1 ABBVIE INC. $1,383.75 02/06/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1202446716
Principal investigator 1 ABBVIE INC. $6,048.40 02/05/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202444767
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,433.53 02/05/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434799
Principal investigator 1 ABBVIE INC. $19,600.00 01/30/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1202443039
Principal investigator 1 ModernaTX, Inc. $6,100.92 01/30/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252977447
Recipient Eli Lilly and Company $3,028.67 01/27/2025 Covered Recipient Physician EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187873309
Principal investigator 1 ModernaTX, Inc. $27,318.20 01/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977347
Principal investigator 1 ModernaTX, Inc. $73,484.84 01/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977367
Principal investigator 1 ModernaTX, Inc. $102.45 01/27/2025 Non-covered Recipient Entity
Neoclinical Research
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977387
Principal investigator 1 ModernaTX, Inc. $6,560.96 01/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977395
Principal investigator 1 ModernaTX, Inc. $107,484.52 01/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977429
Principal investigator 1 ModernaTX, Inc. $6,743.12 01/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977431
Principal investigator 1 ModernaTX, Inc. $23,352.12 01/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977435
Principal investigator 1 ModernaTX, Inc. $2,805.92 01/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977439
Principal investigator 1 ModernaTX, Inc. $9,010.56 01/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977505
Principal investigator 1 ModernaTX, Inc. $1,617.73 01/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007123
Principal investigator 1 ModernaTX, Inc. $45,184.98 01/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007133
Principal investigator 1 ModernaTX, Inc. $17,254.92 01/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007135
Principal investigator 1 ModernaTX, Inc. $37,168.56 01/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007173
Principal investigator 1 ModernaTX, Inc. $123,353.96 01/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007181
Principal investigator 1 ModernaTX, Inc. $1,981.31 01/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007185
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,918.80 01/27/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC
INSPIRE LTE study No dispute reported 06/30/2026 1246434866
Principal investigator 1 ModernaTX, Inc. $399.12 01/21/2025 Non-covered Recipient Entity
Neoclinical Research
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977497
Principal investigator 1 ModernaTX, Inc. $68.30 01/17/2025 Non-covered Recipient Entity
Neoclinical Research
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977513
Principal investigator 1 ModernaTX, Inc. $9,721.92 01/15/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977383
Principal investigator 1 ModernaTX, Inc. $410,847.06 01/15/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977385
Principal investigator 1 ModernaTX, Inc. $85,624.44 01/15/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977397
Principal investigator 1 ModernaTX, Inc. $36,121.28 01/15/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977415
Principal investigator 1 ModernaTX, Inc. $70,098.60 01/15/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977433
Principal investigator 1 ModernaTX, Inc. $62,329.12 01/15/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977507
Principal investigator 1 ModernaTX, Inc. $60,880.56 01/15/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALITY INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977521
Principal investigator 1 ModernaTX, Inc. $68.30 01/14/2025 Non-covered Recipient Entity
Neoclinical Research
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977399
Principal investigator 1 ModernaTX, Inc. $4,100.00 01/10/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252977489
Principal investigator 1 ModernaTX, Inc. $49,583.88 01/08/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252977339
Principal investigator 1 ModernaTX, Inc. $1,165.00 01/08/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252977341
Principal investigator 1 ModernaTX, Inc. $68.30 01/08/2025 Non-covered Recipient Entity
Neoclinical Research
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977377
Principal investigator 1 ModernaTX, Inc. $2,100.00 01/08/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252977403
Principal investigator 1 ModernaTX, Inc. $2,400.00 01/08/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252977405
Principal investigator 1 ModernaTX, Inc. $3,000.00 01/08/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252977445
Principal investigator 1 Eli Lilly and Company $149,068.00 01/07/2025 Non-covered Recipient Entity
SWEET HOPE RESEARCH SPECIALTY INC DBA NEOCLINICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187890102
Principal investigator 1 ModernaTX, Inc. $88.79 01/06/2025 Non-covered Recipient Entity
Neoclinical Research
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977359